Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.66 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | HTR1B | P28222 | 4/20 | 0.57 |
| ▸ | HTR1A | P08908 | 3/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30630423 | 1.00 | HTR1D (0.66) | HTR1DHTR6HTR1BHTR1AHTR2A | |
| SCHEMBL27084803 | 0.90 | HTR1D (0.71) | HTR1DHTR6HTR1BHTR1AHTR2A | |
| SCHEMBL27084869 | 0.90 | HTR1D (0.62) | HTR1DHTR6HTR1BHTR1AHTR2A | |
| SCHEMBL30630353 | 0.90 | HTR1D (0.81) | HTR1DHTR6HTR1BHTR1AHTR2A | |
| SCHEMBL23069149 | 0.90 | HTR1D (0.81) | HTR1DHTR6HTR1BHTR1AHTR2A | |
| SCHEMBL27084706 | 0.90 | HTR1D (0.81) | HTR1DHTR6HTR1BHTR1AHTR2A | |
| SCHEMBL27084856 | 0.89 | HTR1D (0.68) | HTR1DHTR6HTR1BHTR1AHTR2A | |
| SCHEMBL27084953 | 0.89 | HTR1B (0.61) | HTR1DHTR6HTR1BHTR1AHTR2A | |
| SCHEMBL27084676 | 0.87 | HTR1D (0.60) | HTR1DHTR6HTR1BHTR1AHTR2A | |
| SCHEMBL27084921 | 0.87 | HTR1D (0.57) | HTR1DHTR6HTR1BHTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS PATHFINDER LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR1D 53/4885HTR6 13/4885HTR1B 20/4885 |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR1D 53/4885HTR6 13/4885HTR1B 20/4885 |
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | INMT, AANAT, HNMT | HTR1D 664/4885HTR6 57/4885HTR1B 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.